Abstract: Pheochromocytoma and paraganglioma (PPG) are rare and late-diagnosed catecholamine secreting tumors, which may be associated with unrecognized and/or severe cardiomyopathies.
INTRODUCTION
P heochromocytoma is a rare neuroendocrine tumor developed in the adrenal medulla with the ability to synthesize catecholamines. 1, 2 Paragangliomas are also neuroendocrine tumors, but developed in the extra-adrenal sympathetic and parasympathetic nervous systems 3 with a lower incidence (<1 per 300,000 inhabitants per year). 4 These tumors may occur sporadically or secondarily to germline mutations of several tumor-susceptibility genes. 12 The clinical presentation of pheochromocytoma and paraganglioma (PPG) is heterogeneous. Patients can be asymptomatic but may also present multiple and nonspecific symptoms. Furthermore, life-threatening complications may occur. 5 Among these, the prevalence of cardiovascular complications reaches 20% in PPG. 6 It has been proposed that chronic or acute catecholamine intoxication may lead to these structural myocardial alterations. [7] [8] [9] [10] [11] Several cases reports and rare series have investigated cardiomyopathies due to PPG. [12] [13] [14] [15] As a result, different types of PPG-induced cardiomyopathies have been described, both chronic and acute, among which Takotsubo Cardiomyopathies (TTC) are increasingly reported. However, clinical presentation, management, and prognosis of such cardiomyopathies with frequent severe forms remain little known. Moreover, prospective studies have not been performed due to its low incidence.
The aim of the present study was to conduct a systematic literature review to describe acute initial clinical presentation and prognosis of nonischemic cardiomyopathies induced by PPG.
METHODS

Study Design
A National Library of Medicine MEDLINE search was performed using the following MESH terms (''dilated cardiomyopathy'' or ''myocarditis'' or ''acute myocardial infarction'' or ''Takotsubo cardiomyopathy'' or ''cardiogenic shock'' or ''stress cardiomyopathy'') and (''pheochromocytoma'' or ''paraganglioma'') for articles published during the period 1961 to 2012 and undertaken in August 2012. Only English and French language publications were considered. Articles were included according to abstracts or title descriptions with the diagnosis of secondary cardiomyopathy due to catecholaminergic secreting tumors. All included manuscripts were reviewed. Only articles (including case reports, series of case reports, literature review, meta-analysis, and letters to the editor) with diagnosis of cardiomyopathy due to a confirmed catecholaminergic secreting tumor (pheochromocytoma or paraganglioma) revealed by acute symptoms were retained.
In each retained article, clinical, biological, echocardiographic, coronary angiographic, and survival data were available and reportable.
Articles were excluded if cases were not described individually, if the information provided was insufficiently detailed, or if the diagnosis of cardiomyopathy was not possible retrospectively with the available data. Each case without described left ventricle morphology or kinetics, either by echocardiography or coronary angiography, or left ventricle morphology at autopsy examination were also excluded. Cases with significant coronary artery stenosis, described in either angiography or autopsy report, which could explain the clinical presentation as well as obstructive hypertrophic cardiomyopathies were excluded. Reports were screened for duplication and duplicated data were excluded.
Each article was blindly and successively read by 2 endocrinologists and 2 cardiologists in order to complete the dataset. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines 16 were used to guide this review.
This study did not involve human subjects, so informed consent was not required. In addition, no approval was required from an institutional review board.
Cardiomyopathy Classification
For each case report, a diagnosis was retrospectively assessed according to the current literature, regardless of the authors' diagnosis. Thereafter, cases were classified into 2 types of cardiomyopathies: those called Takotsubo Cardiomyopathy (TTC) and meeting the John Hopkins criteria 9, 17 (except for the recovery item, which was used as an endpoint data in the analysis), and those that did not meet this description, termed herein Catecholamine Cardiomyopathy (CC). According to current Mayo Clinic criteria, pheochromocytoma had to be excluded before TCC diagnosis was made. 19 Left ventricular ejection fraction (LVEF) and kinetic abnormalities, described on echocardiography and angiography reports, were used to assess diagnosis. Initial LV systolic dysfunction was classified as severe when LVEF was measured <30%.
Data Assessment
The following data were assessed at acute initial presentation in this analysis: clinical data ( 
Statistical Analysis
Statistical analysis was performed using Stata software, version 13 (StataCorp, College Station). The tests were 2-sided, with a type I error set at a¼0.05. Means and standard deviations (SD) or medians and interquartile ranges are presented for continuous variables according to statistical distribution, whereas frequencies and associated percentages were calculated for categorical parameters. Comparisons between the independent groups TTC and CC, presence of the items ''deaths'' and ''recovery,'' were performed using the chi square test or Fisher's exact test for categorical variables and with Student's t test or the MannWhitney test for quantitative variables (with normality verified by Shapiro-Wilk test and homoscedasticity by the Fisher-Snedecor test). Given that the distribution of TTC and CC pathologies varied over time, it was deemed relevant to consider an adjustment based on the year of publication using regression random-effects models taking into account between-and within-study variability. Finally, multivariate analyses (logistic regression model with deaths and recovery as dependent variables) were performed to study the effect of TCC/CC on outcomes adjusted on fixed parameters according to (1) clinical relevance and (2) univariate results presented in supplemental data. Between-factor interactions were tested and results expressed as odds-ratios (OR) and 95% confidence intervals (95% CI).
RESULTS
The number of cases that met the inclusion criteria for this systematic review was 145 ( Fig. 1 ) of which 49 TTC (33.8%) and 96 CC (66.2%) were identified. Eighty-three (57.2%) reported patients were women. There was no difference in the mean age between both groups (44.6 AE 16.1 years in TTC vs 40.5 AE 14.2 years in CC, P ¼ 0.12). The reported age ranged from 8 to 86 years. The year of publication of the case reports is presented in Figure 2 .
Among the 145 cases, 1 case of CC (0.7%) was diagnosed after autopsy and 3 cases of CC (2.1%) after heart transplantation.
There were no observed differences in the delay of diagnosis (n ¼ 89 cases) between the TTC group and CC group (105 days vs 180 days, P ¼ 0.78).
Characteristics of Catecholamine-Secreting Tumors
In the majority of cases (131/145, 90.3%), an adrenal pheochromocytoma was reported (89.8% of TTC vs 90.6% of CC, P ¼ 1.00). Only 14 (9.7%) paraganglioma were observed, located in the abdomen in 12 cases (8.3%) and in the neck in 2 cases (1.4%). Only 4 (2.8%) metastatic and 8 (5.5%) bilateral forms were documented. Five (10.2%) abdominal paraganglioma were observed in the TTC group vs 7 (7.3%) in the CC group (P ¼ 0.54). The 2 observed cervical paraganglioma were in the CC group.
With regard to genetic presentation, 7 patients (4.8%) were found in the setting of type 2 multiple endocrine neoplasia, 3 (2.1%) in neurofibromatosis, and 1 (0.7%) in von Hippel Lindau syndrome. There were 3 (2.1%) recurrent forms, 1 (2.0%) among TTC, and 2 (2.1%) among CC (P ¼ 1.00). No difference in terms of tumor size was observed between both groups (5.8 AE 2.5 cm for TTC vs 6.1 AE 2.7 cm for CC, P ¼ 0.62).
Clinical Characteristics at Initial Presentation
A history of hypertension was reported in 48 (33.1%) patients (34.7% in TTC vs 32.3% in CC, P ¼ 0.77). There was no difference between the groups with regard to cardiovascular risk factors. Their global prevalence was 12.4% for diabetes, 7.6% for active smoking, 6.2% for dyslipidemia, and 6.2% for history of familial cardio-vascular event. One TTC and 3 CC were found in the setting of pregnancy.
Clinical features of cardiomyopathy at initial presentation are reported in Table 1 Chest radiography data were documented in 82 (56.6%) cases. Cardiomegaly (10.5% vs 39.7%, P ¼ 0.02) was more often observed in the CC group.
Transthoracic Echocardiography
Echocardiographic data were available in 133 cases (91.7%): 42 (85.7%) in the TTC group and 91 (94.8%) in the CC group (P ¼ 0.11) ( Table 2 ).
In the total population, left ventricle dilation (50.4%) was more frequent than hypertrophic cardiopathy (10.5%). LV dilation was observed more frequently in the CC group (14.3% vs 67.0%, P < 0.001).
Left ventricular ejection fraction at initial presentation was described in 99 cases (68.3%): median LVEF was similar in both groups: 30.0% (23.0-35.0) in the TTC group vs 26.0% (20.0-35.5) in the CC group (P ¼ 0.47). Furthermore, no difference in proportion of patients with a severe LV systolic dysfunction (LV ejection fraction < 30%) was observed between the 2 groups (40.7% in TTC vs 56.9% in CC, P ¼ 0.15).
Coronary Artery and LV Angiography
Coronary artery and LV angiography were documented in 89 cases: 38 (77.6%) of TTC and 51 (53.1%) of CC (P ¼ 0.004). Nonsignificant atheroma was found in only 3 (7.9%) TTC and in 6 (11.8%) CC (P ¼ 0.73). Furthermore, as described pre- 
Management and Outcome
Management
Preoperative medical and invasive treatment was similar in both groups (Table 3) .
Furthermore, a complete surgical catecholaminesecreting tumor resection was reported in 127/129 (98.4%) Tables 1 and 2 ).
DISCUSSION
The present review is, to our knowledge, the largest case series dealing with cardiomyopathies complicating catecholamine-secreting tumors. 6, 12, 14, [20] [21] [22] Knowledge of these pathologies is currently limited by difficulties in diagnosing PPG and the variability in clinical manifestations. This results in a lack of prospective studies and the publication of mainly isolated case reports. This review may hence help clinicians to better understand this pathology and to identify patients in whom diagnosis of PPG needs to be established rapidly.
Clinical and Paraclinical Presentation
Similar prevalences of both cardiological (dyspnea, chest pain, or weakness) and specific pheochromocytoma symptoms (headaches, palpitations, sweating, and digestive signs) were observed at clinical onset in both identified TTC and CC populations (Table 1) . These prevalences were comparable to those described in the literature regarding Takotsubo Cardiomyopathy (TTC) 8, 10, 11, 23, 24, 25 and PPG. 1 However, high blood pressure at initial presentation (83.8% of total population) is not usually described during TTC and in heart failure with reduced left ventricular ejection fraction. 23 Thus, the presence of a PPG had to be eliminated after the diagnosis of a TTC or unexplained dilated cardiomyopathy, especially in the presence of hypertension at clinical onset. More frequent acute pulmonary edema and electric ventricular hypertrophy were observed in the CC group. A more important LV dilation was also observed in the CC group at baseline.
Prognosis
The present review confirms the severity of these cardiomyopathies with a 7.6% in-hospital mortality rate and a 51.0% cardiogenic shock rate at initial presentation, as previously described, 12 versus only 6% in all-cause TTC. 26, 27, 24, 28 Of importance, this literature review enabled us to identify 2 different types of cardiomyopathies due to PPG having similar initial acute presentations but different evolutions and prognosis, namely (i) Takotsubo Cardiomyopathy, also called ''stress cardiomyopathy, '' 18 with a higher rate of LV function recovery and (ii) more chronic catecholaminergic cardiomyopathies, including dilated cardiomyopathies revealed by acute heart failure, with a lower recovery rate. Indeed, this study nonetheless highlights certain key differences between these 2 populations, which must be interpreted cautiously. At initial presentation, the proportion of patients with LVEF < 30% was similar in both groups. The proportion of LV systolic function recovery was only 50% via medical treatment while reaching 82.2% after surgery. However, there was a quicker and better recovery of LV systolic dysfunction in the TTC group before and after surgery. End of catecholamine exposure due to surgical resection was systematically associated with an improvement in LV systolic function in both groups. Evolution of CC was likely longer due to chronic exposure even if the acute initial presentation was quite similar. The CC group probably constituted a more heterogeneous group which included mainly dilated or nonobstructive hypertrophic cardiomyopathies. This latter observation nevertheless emphasizes that a large segment of this group likely suffered from a more chronic and long-standing catecholaminergic intoxication, leading to structural myocardial alterations (fibrosis and inflammation). This chronic exposure may explain the lower level of LVEF recovery in this group.
Pathophysiology
These 2 types of PPG-induced cardiomyopathies appear to have different pathophysiological pathways. Adrenergic cardiac toxicity is now well-documented. 29 An acute catecholaminergic stress in TTC (physical or emotional stress) inundates myocardial b receptors leading to a stunning of the left ventricle 7, 8, 10, 11, 30 and slight histological apoptosis. 31 In the case of chronic adrenergic exposure, the heart is able to adapt. Desensitization is mediated by adrenergic receptors phosphorylation via G-protein coupled receptor kinase (GRKs) followed by binding to b-arrestin promoting the receptor internalization. 32 Moreover, recent studies demonstrate that secretion of catecholamin in the adrenal medulla is regulated by GRK2 and barrestin suggesting a GRK2/b-arrestin-mediated cross talk between adrenal gland and the heart. 33 In the same way, protein kinase A (PKA) is able to promote desensitization and downregulation of b-adrenergic receptors in cardiomyocytes through PIP 3 and cAMP signaling modulation. 34 In spite of this regulation, chronic catecholamin administration causes interstitial fibrosis, promotes cardiac apoptosis, and induces contractile dysfunction through left ventricular dilatation. 29 In the CC population, repetitive myocardial aggression due to longer catecholaminergic exposure could explain LV hypertrophy, extended histological fibrosis, and extracellular matrix collagen turnover [35] [36] [37] 5, 38 all of which lead to a lower recovery rate. This is all the more significant as myocardial fibrosis has been associated with a poorer prognosis. 39 Such delay in diagnosis may lead to a deterioration in systolic and diastolic functions thereby influencing the recovery rate, and ultimately, the type of cardiomyopathy.
The Importance of Time of Diagnosis
In the present study, diagnosis time was estimated at about 2 years after the first report of PPG signs. This delay is classically described at 3 years for pheochromocytoma 1 and even 5 years for paraganglioma. 40 Moreover, we found several cases with recurrence of cardiac episodes (15.5%). This highlights the necessity of an early diagnosis of PPG. Furthermore, favorable evolution after complete surgery should lead clinicians to conduct a systematic biochemical screening when faced with these PPG-suggestive situations.
Moreover, we found that larger tumor sizes, recurrent tumors as well as head and neck locations were associated with a poorer prognosis (supplementary data Table 1 ). Accordingly, tumor size has been previously demonstrated as a predictive factor of malignancy, tumor recurrence, and a poorer prognosis in PPG. 41, 42, 43 
Clinical Implications
Clinical consequences for clinicians and especially cardiologists are particularly important: discovery of any Takotsubo Cardiomyopathy or unexplained dilated cardiomyopathy without coronary significant lesion should lead to an active search for a PPG. Indeed, association of headaches, sweating, or palpitations episodes classically evokes the presence of a PPG. Initial hypertension, sinus tachycardia, electrical left ventricular hypertrophy are strong supplemental arguments in driving the search for PPG. In the case of TTC, an emotional stress must not discount the suspicion, because of the possible emotional trigger in a PPG crisis. 7 Indeed, a triggering factor, whether physical or emotional, has been reported in $10 % of the cases studied. 39, 44, 45, 12 The currently recommended tests to detect PPG are sampling of urinary methoxylated metabolites and plasma-free metanephrines. 1 Concomitantly for the endocrinologist, the diagnosis of a PPG should invariably lead to cardiac imagery (echocardiography or Magnetic Resonance Imaging) in order to detect a potential silent chronic cardiomyopathy. Such an approach could improve perioperative management and shorten the delay in introducing heart failure-specific drugs.
Study Limitations
In spite of the exhaustive collection of all biological values, their interpretation has not been possible. Indeed, there is currently no international standardization procedure regarding urinary or plasma catecholamine metabolite assays, or troponin or Brain Natriuretic Peptides and its precursors, nor with regard to their normal values, units, or dosage techniques, even if such values would have been highly informative. 46 For the oldest articles, one could expect that certain Takotsubo cardiomyopathies, not described before 1990, may have been designated as a nonspecific cardiomyopathy therefore precluding their inclusion in the TTC group herein. Nevertheless, this situation involves a minority of articles of which some may have indeed been included in the Takotsubo group owing to a precise description of the systolic dysfunction.
This systematic review also suffers from an inherent bias usually associated with retrospective studies. The descriptive quality of case reports was heterogeneous which rendered the classification and analysis interpretation somewhat difficult for some articles. The wide chronological range also leads to heterogeneous knowledge and therapeutic techniques, all of which may influence prognosis interpretation.
Nevertheless, this review enabled us to collect the largest series of case reports dealing with cardiomyopathies associated with PPG. This is a major point, given the rarity of these tumors, the difficulties with regard to their diagnosis as well as poor prognosis, all of which do not allow prospective studies.
CONCLUSION
Pheochromocytoma and paraganglioma can lead to chronic and acute cardiomyopathies with the same acute and life-threatening clinical onset. Takotsubo cardiomyopathy displayed a better LV systolic function recovery. Diagnosis of an unexplained dilated cardiomyopathy without coronary stenosis or any TTC should encourage clinicians to eliminate the presence of PPG.
